Castle Biosciences (CSTL) Balance Sheet: Assets & Liabilities

Castle Biosciences (CSTL) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Castle Biosciences reported total assets of $578.56M and total liabilities of $107.68M. Shareholders' equity was $470.87M, up 3.3% from $455.83M a year earlier. Total debt stood at $10.06M against $299.50M in cash and short-term investments, a net cash position of $289.45M. That puts debt-to-equity at 0.02, compared with 0.06 a year earlier.

Castle Biosciences Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Castle Biosciences, Inc. (CSTL) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Current Assets
Cash and Cash Equivalents	116.73	119.71	98.84	122.95	329.63	409.85	98.85	4.48	1.21
Short-Term Investments	182.78	173.42	144.26	135.68	0.00	0.00	0.00	0.00	0.00
Cash & Short-Term Investments	299.51	293.13	243.10	258.63	329.63	409.85	98.85	4.48	1.21
Accounts Receivable	43.38	51.22	38.30	23.48	17.28	12.76	14.65	12.09	4.65
Inventory	10.25	8.14	7.94	3.98	2.02	2.22	1.24	0.88	0.30
Other Current Assets	7.96	7.67	6.29	6.21	4.81	4.77	1.95	0.68	0.52
Total Current Assets	361.10	360.15	295.64	292.29	353.74	429.59	116.68	18.13	6.68
Non-Current Assets
Property, Plant & Equipment (Net)	112.24	62.71	37.74	26.50	16.88	7.10	2.06	1.53	1.47
Long-Term Investments	0.00	0.00	0.00	0.00	1.31	0.00	0.00	2.53	1.56
Goodwill	10.69	10.69	117.34	10.69	88.92	0.00	0.00	0.00	0.00
Intangible Assets	88.88	95.54	106.64	115.66	88.92	0.00	0.00	0.00	0.04
Other Non-Current Assets	3.77	2.15	2.63	1.11	3.02	2.63	1.01	2.75	1.63
Total Non-Current Assets	217.46	171.08	157.71	155.04	108.83	9.73	3.07	4.28	3.14
Total Assets	578.56	531.24	453.34	447.33	462.57	439.33	119.75	22.40	9.82
Current Liabilities
Accounts Payable	18.71	6.90	10.27	4.73	2.55	2.10	1.87	1.45	1.12
Short-Term Debt	0.42	1.94	1.14	1.78	1.18	0.00	5.83	0.00	1.00
Current Portion of Long-Term Debt	0.42	0.28	-	-	-	-	-	-	-
Accrued Liabilities	5.89	4.92	36.26	3.95	21.16	11.81	-	-	-
Deferred Revenue	0.00	0.00	0.00	0.00	0.00	6.62	0.00	0.00	0.01
Other Current Liabilities	3.13	39.47	0.54	0.42	0.56	11.89	7.51	5.28	3.08
Total Current Liabilities	68.68	49.39	47.67	36.13	24.89	20.88	15.29	6.74	5.22
Non-Current Liabilities
Long-Term Debt	9.64	24.40	14.20	11.62	7.02	0.00	19.29	24.50	17.60
Deferred Tax Liabilities	2.34	1.61	0.21	0.43	0.64	0.00	0.00	0.00	0.00
Other Non-Current Liabilities	1.50	0.00	0.21	0.52	19.05	1.03	0.06	1.24	1.27
Total Non-Current Liabilities	39.01	26.01	14.40	12.05	25.95	2.76	19.34	25.74	18.87
Total Liabilities	107.68	75.40	62.07	48.18	50.83	23.64	34.63	32.47	24.09
Stockholders' Equity
Common Stock	0.03	0.03	0.03	0.03	0.03	0.03	0.02	0.00	0.00
Retained Earnings	-224.28	-200.13	-218.37	-160.91	-93.77	-62.50	-52.21	-57.49	-51.12
Accumulated Other Comprehensive Income	0.27	0.23	0.14	-0.38	0.00	0.00	0.00	-0.91	-0.64
Additional Paid-in Capital	694.86	655.70	609.48	560.41	505.48	478.16	137.31	-2.09	0.64
Shares Outstanding	29.69	28.48	27.41	26.55	25.38	-	-	-	-
Total Stockholders' Equity	470.87	455.84	391.27	399.15	411.74	415.69	85.11	-10.07	-14.27
Total Liabilities & Equity	578.56	531.24	453.34	447.33	462.57	439.33	119.75	22.40	9.82

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Castle Biosciences Balance Sheet

How much debt does Castle Biosciences have?

Castle Biosciences had total debt of $10.06M as of Dec 31, 2025, against $299.50M in cash and short-term investments. Its debt-to-equity ratio was 0.02. Total debt was $26.34M a year earlier.

What are Castle Biosciences's total assets?

Castle Biosciences reported total assets of $578.56M as of Dec 31, 2025, up 8.9% from $531.24M a year earlier. Total liabilities were $107.68M.

What is Castle Biosciences's shareholders' equity?

Castle Biosciences's shareholders' equity was $470.87M as of Dec 31, 2025, or about $15.86 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition